Evidence map›Paper›PMID 31645175›Full record

ArticleNucleosides, nucleotides & nucleic acids2020

Limits of using oligonucleotides for allele-selective inhibition at trinucleotide repeat sequences - targeting the CAG repeat within ataxin-1.

Jiaxin Hu, David R Corey

Open access · greenAbstract read
In one paragraph

Article in Nucleosides, nucleotides & nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jiaxin HuDepartments of Pharmacology and Biochemistry, UT Southwestern Medical Center at Dallas, Dallas, TX, USA.
David R CoreyDepartments of Pharmacology and Biochemistry, UT Southwestern Medical Center at Dallas, Dallas, TX, USA.
The University of Texas Southwestern Medical Center · US

Funding

Recognition of Cellular Targets by single and double-stranded nucleic acidsR35GM118103 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI David R Corey · 2016 to 2026
$5.7M
NIGMS NIH HHS R35 GM118103
6 · The paper itself

Abstract

Trinucleotide repeats are responsible for many genetic diseases. Previous studies have shown that duplex RNAs (dsRNAs) can be used to target expression of a mutant repeat allele while leaving expression of the wild-type allele untouched, creating opportunities for allele-selective inhibition and better therapeutic outcomes. In contrast to successes with other genes, we report here that we cannot achieve allele-selective inhibition when targeting the expanded CAG repeat within Ataxin-1 (ATXN1), the cause of spinal cerebellar ataxia-1 (SCA1). The most likely explanation for this unfavorable outcome is that the mean CAG repeat number within wild-type ATXN1 is relatively high compared to other trinucleotide repeat diseases. Because the wild-type repeat number is high, it is likely that there is poor discrimination between the mutant and wild-type repeat and less opportunity for allele-selective inhibition across the entire spectrum of mutations found in SCA1 patients. Our data support the conclusion that the potential for multiple cooperative binding interactions is a critical factor governing allele-selective recognition of trinucleotide repeat genes by duplex RNAs. These results should be helpful in predicting which diseases and which patients are most likely to benefit from allele-selective targeting of expanded repeats.

Indexed as

AllelesGene Expression RegulationGene SilencingOligonucleotidesTrinucleotide RepeatsAtaxin-1Cells, CulturedFibroblastsHumansMutationRNA, Double-StrandedRNA InterferenceAtaxin-1ATXN1 protein, humanOligonucleotidesRNA, Double-Strandedallele-selective inhibitionataxin-1 (ATXN1)Duplex RNARNAispinal cerebellar ataxia-1 (SCA1)trinucleotide repeat

Identifiers

PMID31645175
PMCPMC7174099
OpenAlexW2981354889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.